Oxygen generating biomaterial improves the function and efficacy of beta cells within a macroencapsulation device

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Medical Devices

Background:

• Tissue-engineered devices hold promise for improving human health but face challenges like insufficient oxygen transport, leading to cell death.
• Oxygen deprivation is a critical factor limiting the success of clinical cell transplantation and the efficacy of macroencapsulation devices.
• Developing methods to ensure adequate oxygen supply is crucial for advancing cell-based therapies.

Purpose of the Study:

• To develop and evaluate an in situ oxygen-generating material (OxySite) for improving cell viability and function in macroencapsulation devices.
• To assess the efficacy of OxySite in supporting beta cell and islet function under hypoxic conditions.
• To demonstrate the therapeutic potential of OxySite for treating type 1 diabetes in a preclinical model.

Main Methods:

• Development of OxySite: polydimethylsiloxane (PDMS) encapsulated solid calcium peroxide.
• In vitro testing of OxySite's oxygen generation and its effect on beta cell and islet viability and function under hypoxia.
• In vivo implantation of macroencapsulation devices with and without OxySite in a diabetic rodent model to evaluate graft efficacy and insulin production.
• Validation of OxySite with human islets at elevated densities.

Main Results:

• OxySite significantly enhanced beta cell and islet viability and function under extreme hypoxic conditions.
• Implanted macrodevices containing OxySite demonstrated improved graft efficacy and insulin production in diabetic rodents.
• The material proved advantageous for human islets at higher loading densities, confirming its broad applicability.
• OxySite provides a localized and controllable oxygen supply, overcoming a key limitation in cell-based therapies.

Conclusions:

• OxySite is an effective in situ oxygen-generating biomaterial that supports cellular function and enhances the efficacy of macroencapsulation devices.
• This approach offers a significant advancement for cell-based therapies, particularly for type 1 diabetes treatment.
• The biomaterial platform has broad potential for improving the therapeutic outcomes of various cell transplantation strategies by addressing oxygen supply limitations.